Upgrade

Finvezto Toolkit

Balaxi Pharmaceuticals Q2 FY27: revenue up 44.8% to ₹81 Cr, net profit up 450.0% to ₹1 Cr

Results · 12 Nov 2026 · Balaxi Pharmaceuticals (BALAXI)

Q2 FY27 results
Q2 FY27₹ CrYoY
Revenue81+44.8%
Operating profit5+325.0%
Net profit1+450.0%

Balaxi Pharmaceuticals reported Q2 FY27 consolidated revenue from operations of Rs 81.37 crore, up 44.85% YoY, with EBITDA of Rs 5.12 crore, up 338.19%, and PAT of Rs 1.15 crore, up 450.29%, for the quarter ended September 30, 2026.

H1 FY27 revenue rose 27.68% YoY to Rs 162.05 crore with PAT up 390.30% to Rs 2.45 crore, and the company added 31 new product registrations while its Jadcherla oral solid dosage facility became operational.

Operating margin was 6.3%, up 4.1 pp on a year earlier and up 0.4 pp on the quarter before.

NSE filing (PDF) · Company page · Results tracker

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.